# Vertex Pharmaceuticals Incorporated trials: 249 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 249 trials with Vertex Pharmaceuticals Incorporated as lead sponsor, 13 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Vertex Pharmaceuticals Incorporated: 249 rows for $12.45, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 2 rows a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/vertex-pharmaceuticals-incorporated

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 249
- Recruiting or not yet: 13
- Read on: November 19, 2026

## Trials

The 25 newest of 249, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| October 22, 2026 | NCT07890909 | A Phase 3b Study of Participant Experience on Povetacicept Administered Via Autoinjector as Compared to Sibeprenlimab Administered Via... | Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | Immunoglobulin A Nephropathy | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07890909) |
| October 9, 2026 | NCT07868926 | Absorption, Distribution, Metabolism, and Excretion of 14C-VX-407 After a Single Oral Dose | Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07868926) |
| September 10, 2026 | NCT07813039 | A Phase 1 Relative Bioavailability Study of a VX-581 Tablet Formulation | Vertex Pharmaceuticals Incorporated | Phase 1 | Active not recruiting | Cystic Fibrosis | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07813039) |
| September 8, 2026 | NCT07807995 | A Phase 3 Open-Label Study of Long-term Treatment With Povetacicept in Adults With Immunoglobulin A Nephropathy | Vertex Pharmaceuticals Incorporated | Phase 3 | Enrolling by invitation | Immunoglobulin A Nephropathy | 605 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07807995) |
| August 28, 2026 | NCT07792408 | Effects of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives | Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 148 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07792408) |
| May 13, 2026 | NCT07584434 | A Phase 1, First-in-human Study of VX-433 | Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Narcolepsy Type 1 (NT1) | 118 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07584434) |
| May 6, 2026 | NCT07570069 | Effects of Efavirenz on the Pharmacokinetics of Suzetrigine in Healthy Participants | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Pain | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07570069) |
| April 20, 2026 | NCT07538570 | Evaluation of Pain Treatment After Total Knee Arthroplasty | Vertex Pharmaceuticals Incorporated | Phase 4 | Completed | Pain | 66 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07538570) |
| March 30, 2026 | NCT07501702 | A Phase 2 Study to Evaluate Povetacicept in Adults With Generalized Myasthenia Gravis | Vertex Pharmaceuticals Incorporated | Phase 2 | Active not recruiting | Myasthenia Gravis, Generalized | 34 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07501702) |
| February 27, 2026 | NCT07437105 | Dose Escalation Study Evaluating the Safety and Pharmacokinetics of VX-272 in Healthy Participants | Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Cystic Fibrosis | 160 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07437105) |
| January 30, 2026 | NCT07378865 | Evaluation of the Excretion of Suzetrigine Into Breast Milk in Healthy Lactating Female Participants | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Pain | 13 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07378865) |
| January 16, 2026 | NCT07349394 | Effect of Vanzacaftor/Tezacaftor/Deutivacaftor (VNZ/TEZ/D-IVA) on the PK of Rosuvastatin in Healthy Participants | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Cystic Fibrosis | 18 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07349394) |
| December 16, 2025 | NCT07283770 | Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis | Vertex Pharmaceuticals Incorporated | Phase 1 | Recruiting | Cystic Fibrosis | 152 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07283770) |
| November 17, 2025 | NCT07231419 | Evaluation of Efficacy and Safety of Suzetrigine (SUZ) for Pain Associated With Diabetic Peripheral Neuropathy | Vertex Pharmaceuticals Incorporated | Phase 3 | Recruiting | Diabetic Peripheral Neuropathic Pain | 734 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231419) |
| October 2, 2025 | NCT07204275 | Evaluation of Efficacy, Safety, and Tolerability of Povetacicept in Participants With Primary Membranous Nephropathy (pMN) | Vertex Pharmaceuticals Incorporated | Phase 2/3 | Recruiting | Primary Membranous Nephropathy | 176 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07204275) |
| September 8, 2025 | NCT07161037 | Phase 2a Study of VX-407 in Participants With ADPKD Who Have a Subset of PKD1 Gene Variants (AGLOW) | Vertex Pharmaceuticals Incorporated | Phase 2 | Active not recruiting | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 26 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07161037) |
| July 20, 2025 | NCT07074327 | Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 74 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07074327) |
| June 15, 2025 | NCT07022119 | A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Autosomal Dominant Polycystic Kidney Disease (ADPKD) | 32 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022119) |
| June 8, 2025 | NCT07010406 | A Study to Evaluate the Relative Bioavailability of Povetacicept Formulations and Bioequivalence of Povetacicept Presentations | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Healthy Volunteers | 136 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07010406) |
| April 14, 2025 | NCT06926621 | A Study of Long-term Safety and Efficacy of VX-670 in Participants With Myotonic Dystrophy Type I | Vertex Pharmaceuticals Incorporated | Phase 2 | Enrolling by invitation | Myotonic Dystrophy Type 1 (DM1) | 44 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926621) |
| March 21, 2025 | NCT06887972 | A Single-Arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Aesthetic or Reconstructive Surgeries | Vertex Pharmaceuticals Incorporated | Phase 4 | Completed | Acute Pain | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06887972) |
| March 21, 2025 | NCT06887959 | A Single-arm Study Evaluating the Effectiveness and Safety of Suzetrigine (SUZ) for Acute Pain After Selected Surgeries | Vertex Pharmaceuticals Incorporated | Phase 4 | Completed | Acute Pain | 47 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06887959) |
| March 20, 2025 | NCT06886269 | A Study to Evaluate How the Body Processes 14C-VX-993 After a Single Oral Dose | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Pain | 8 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06886269) |
| March 6, 2025 | NCT06861413 | A Phase 1 Study to Evaluate the Relative Bioavailability of a VX-828 Tablet Formulation | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Cystic Fibrosis | 68 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06861413) |
| February 19, 2025 | NCT06834009 | A Study of Suzetrigine (SUZ) Spray-dried Dispersion (SSD) in Healthy Adult Panelists | Vertex Pharmaceuticals Incorporated | Phase 1 | Completed | Pain | 10 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06834009) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 74 |
| Phase 1/2 | 9 |
| Phase 2 | 61 |
| Phase 2/3 | 6 |
| Phase 3 | 81 |
| Phase 4 | 6 |
| Not applicable | 5 |
| Observational | 7 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 194 |
| Terminated | 18 |
| Active not recruiting | 14 |
| Recruiting | 13 |
| Enrolling by invitation | 4 |
| Approved for marketing | 4 |
| Withdrawn | 2 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Cystic Fibrosis | 117 |
| Pain | 26 |
| Hepatitis C | 19 |
| Genetic Diseases, Inborn | 11 |
| Hepatitis C, Chronic | 10 |
| Acute Pain | 10 |
| Polycystic Kidney, Autosomal Dominant | 7 |
| Arthritis, Rheumatoid | 6 |
| Hematologic Diseases | 6 |
| Hemoglobinopathies | 6 |
| alpha 1-Antitrypsin Deficiency | 5 |
| Anemia, Sickle Cell | 5 |
| Pancreatic Diseases | 5 |
| Lung Diseases | 5 |
| Infant, Newborn, Diseases | 5 |
| beta-Thalassemia | 4 |
| Thalassemia | 4 |
| Fibrosis | 4 |
| Respiratory Tract Diseases | 4 |
| Pathologic Processes | 4 |
| Digestive System Diseases | 3 |
| Diabetes Mellitus, Type 1 | 3 |
| Glomerulosclerosis, Focal Segmental | 3 |
| Myotonic Dystrophy | 2 |
| Myotonia | 2 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Pharmaceutical companies in the United States](https://specstream.ai/data/businesses/pharmaceutical-companies/united-states)
- [Jewelry manufacturers in the United States](https://specstream.ai/data/businesses/jewelry-manufacturers/united-states)
- [Vocational and technical schools in the United States](https://specstream.ai/data/businesses/vocational-and-technical-schools/united-states)
- [Fire and water damage restoration companies in the United States](https://specstream.ai/data/businesses/fire-and-water-damage-restoration-companies/united-states)
- [Sake bars in the United States](https://specstream.ai/data/businesses/sake-bars/united-states)
- [Colombian restaurants in the United States](https://specstream.ai/data/businesses/colombian-restaurants/united-states)
